Across TCGA pan-cancer cohorts, IGHD5-18 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IGHD5-18 data layer compared with 13 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher IGHD5-18 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHD5-18 expression acts as an unfavorable survival marker.
COAD are the cancer types where IGHD5-18 Mutation most reproducibly stratifies survival.